All In Biotech

Drug Trial Radar · NCT01796002

Efficacy and Safety of Romidepsin CHOP vs CHOP in Patients With Untreated Peripheral T-Cell Lymphoma

Phase 3 Multi-center Randomized Study to Compare Efficacy and Safety of Romidepsin CHOP (Ro-CHOP) Versus CHOP in Patients With Previously Untreated Peripheral T-cell Lymphoma

Last checked: Nov 20, 2026Latest source record: Jan 10, 2023 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. Randomized with 421 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

421

Actual

Start

Jan 2013

Primary completion

Dec 13, 2019

Study completion Dec 13, 2022

Sponsor

Lead sponsor
The Lymphoma Academic Research OrganisationAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Feb 21, 2013

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 18 years, up to 80 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Primary objective of the study is to compare the efficacy of romidepsin when administered with CHOP versus CHOP alone in subjects with previously untreated peripheral T-cell lymphoma (PTCL) in terms of progression-free survival (PFS) assessed according to Response criteria for malignant lymphoma 1999 by a Response Adjudication Committee (RAC).

Conditions

  • Peripheral T-cell Lymphoma

Interventions

  • Romidepsin + CHOPDrug

    Ro-CHOP administered in 3 week cycles for 6 cycles or until progression Romidepsin is administered at a dose of 12 mg/m² IV on day 1 and day 8 every 3 weeks.

  • CHOPDrug

    CHOP (cyclophosphamide, doxorubicin, vincristine and prednisone) administered in 3 week cycles for 6 cycles.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. The primary efficacy endpoint is Progression Free SurvivalTime frame: 60 months

Locations

131 sites in 8 countries. Site status is shown where the registry gives one.

  • ZNA Stuivenberg

    Antwerp, Belgium

  • A.Z. Sint Jan AV

    Bruges, Belgium

  • Institut Jules Bordet

    Brussels, Belgium

  • UCL Louvain Saint Luc

    Brussels, Belgium

  • ULB - Hôpital Erasme

    Brussels, Belgium

  • Grand Hôpital de Charleroi

    Charleroi, Belgium

  • Hôpital Jolimont

    Haine-Saint-Paul, Belgium

  • AZ VUB

    Jette, Belgium

  • AZ Groeninge

    Kortrijk, Belgium

  • CHC - Clinique Saint Joseph

    Liège, Belgium

  • CHU de Liege

    Liège, Belgium

  • CHU Mont Godinne

    Yvoir, Belgium

  • CHU d'Amiens

    Amiens, France

  • CHU d'Angers

    Angers, France

  • CH de Annecy

    Annecy, France

  • CH Henri Duffaut

    Avignon, France

  • CH Côte Basque

    Bayonne, France

  • CHU Jean Minjoz

    Besançon, France

  • CH de Béziers

    Béziers, France

  • CHU de Bordeaux - Hôpital Haut Lévêque - Centre François Magendie

    Bordeaux, France

  • Institut Bergonié

    Bordeaux, France

  • Polyclinique Bordeaux Nord Aquitaine

    Bordeaux, France

  • CH du Dr Duchenne

    Boulogne-sur-Mer, France

  • CH de Bourg en Bresse

    Bourg-en-Bresse, France

  • Centre François Baclesse

    Caen, France

  • Institut d'Hématologie de Basse-Normandie

    Caen, France

  • CH de Chalon sur Saône

    Chalon-sur-Saône, France

  • CH de Chambéry

    Chambéry, France

  • Hôpital Antoine Béclère

    Clamart, France

  • CHU Estaing

    Clermont-Ferrand, France

  • Hôpital Pasteur

    Colmar, France

  • CH Sud Francilien de Corbeil

    Corbeil-Essonnes, France

  • CHU Henri Mondor

    Créteil, France

  • CHU de Dijon

    Dijon, France

  • CH de Dunkerque

    Dunkirk, France

  • CHU de Grenoble

    Grenoble, France

  • CHD La Roche sur Yon

    La Roche-sur-Yon, France

  • Centre Hospitalier de Versailles - André Mignot

    Le Chesnay, France

  • Hôpital Kremlin Bicêtre

    Le Kremlin-Bicêtre, France

  • CH du Mans

    Le Mans, France

Showing 40 of 131 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.